Managing a malignant orocutaneous fistula: Stem the tide with octreotide?

Internal Medicine Journal

Volumn 32, Issue 4, 2002, Pages 191-192

  Gibson, S ^a   Strutt, R ^a   Chye, Richard ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; OCTREOTIDE;

AGED; ARTICLE; CASE REPORT; CELLULITIS; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFECT; FISTULA; HUMAN; MALE; MANDIBLE FRACTURE; MELANOMA; NAUSEA; OROCUTANEOUS FISTULA; OSTEOMYELITIS; PRIORITY JOURNAL; VOMITING;

AGED; COMBINED MODALITY THERAPY; CUTANEOUS FISTULA; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MANDIBULAR FRACTURES; MELANOMA; MOUTH DISEASES; OCTREOTIDE; OSTEOMYELITIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0036965745     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-0903.2001.00190.x     Document Type: Article

References (3)

1. Nader A, Grace ND. Pharmacological prevention of rebleeding. Gastrointest Endosc Clin N Am 1999; 9: 301-10.
2. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook. Ann Oncol 1999; 10: S31-8.
3. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Medical 1998; 217: 143-52.